About this trial
The study concerns donors and patients receiving allogeneic stem cell haematopoietic transplantation. The aim of the study is to analyse HSC graft content in immune effector T (naive, memory, activated, exhausted) and immunoregulatory cell subtypes (Tregs, iNKT, MDSC) and correlate the results with post-transplant immune reconstitution of those different cell subtypes and clinical events (graft-versus-host-disease, relapse, infections). An ancillary study will focus on the impact of microbiota dysbiosis on post-transplant immune response and regulatory cell subsets.
Eligibility criteria
Qualifiers
patient of the Nancy CHRU, for whom a CSH allograft is planned. or
hematopoietic stem cell donors received at Nancy's CHRU for the duration of the research
Disqualifiers
Positive HIV
active hepatitis B or C infection
Trial design
Treatments tested in this trial
- Blood Sample
- Bone marrow aspiration
- Blood sample
- Allogeneic hematopoietic stem cell sample